

产品名称：莫索尼定
 产品别名：Moxonidine; BDF5895

生物活性:																											
Description	Moxonidine(BDF5895) is a selective agonist at the imidazoline receptor subtype 1, used as antihypertensive agent. Target: I1-R Moxonidine is a centrally acting antihypertensive agent. Mixed Nischarin (I1 imidazoline receptor) and α 2-AR (adrenergic) agonist; displays 40-fold higher affinity for I1 receptors versus α 2-adrenoceptors. Moxonidine reduced stimulated NE overflow (log EC50: -6.15 +/- 0.14). AGN192403, a selective ligand at I1-R, had no influence on the dose-response curve of moxonidine (log EC50: -6.01 +/- 0.25) [1]. The hypotensive and bradycardic actions of moxonidine but not clonidine are mediated through imidazoline receptors and are dependent on intact noradrenergic pathways within the RVLM. Furthermore, the noradrenergic innervation may be associated with a 42 kDa imidazoline receptor protein [2].																										
Solvent&Solubility	In Vitro: DMSO : 20 mg/mL (82.75 mM; Need ultrasonic)																										
		<table border="1"> <thead> <tr> <th>Solvent</th> <th>Mass</th> <th colspan="3"></th> </tr> <tr> <th colspan="2">Concentration</th> <th>1 mg</th> <th>5 mg</th> <th>10 mg</th> </tr> </thead> <tbody> <tr> <td rowspan="3" style="text-align: center;">Preparing Stock Solutions</td> <td style="text-align: center;">1 mM</td> <td style="text-align: center;">4.1377 mL</td> <td style="text-align: center;">20.6885 mL</td> <td style="text-align: center;">41.3770 mL</td> </tr> <tr> <td style="text-align: center;">5 mM</td> <td style="text-align: center;">0.8275 mL</td> <td style="text-align: center;">4.1377 mL</td> <td style="text-align: center;">8.2754 mL</td> </tr> <tr> <td style="text-align: center;">10 mM</td> <td style="text-align: center;">0.4138 mL</td> <td style="text-align: center;">2.0689 mL</td> <td style="text-align: center;">4.1377 mL</td> </tr> </tbody> </table>	Solvent	Mass				Concentration		1 mg	5 mg	10 mg	Preparing Stock Solutions	1 mM	4.1377 mL	20.6885 mL	41.3770 mL	5 mM	0.8275 mL	4.1377 mL	8.2754 mL	10 mM	0.4138 mL	2.0689 mL	4.1377 mL		
	Solvent	Mass																									
	Concentration		1 mg	5 mg	10 mg																						
	Preparing Stock Solutions	1 mM	4.1377 mL	20.6885 mL	41.3770 mL																						
5 mM		0.8275 mL	4.1377 mL	8.2754 mL																							
10 mM		0.4138 mL	2.0689 mL	4.1377 mL																							
*请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液。一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。																											
In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂： ——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶 1.请依序添加每种溶剂： 10% DMSO→40% PEG300 →5% Tween-80 → 45% saline Solubility: \geq 2 mg/mL (8.28 mM); Clear solution 此方案可获得 \geq 2 mg/mL (8.28 mM, 饱和度未知) 的澄清溶液。 以 1 mL 工作液为例，取 100 μ L 20.0 mg/mL 的澄清 DMSO 储备液加到 400 μ L PEG300 中，混合均匀，向上述体系中加入 50 μ L Tween-80，混合均匀；然后继续加入 450 μ L 生理盐水定容至 1 mL。 2.请依序添加每种溶剂： 10% DMSO→ 90% (20% SBE- β -CD in saline) Solubility: \geq 2 mg/mL (8.28 mM); Clear solution 此方案可获得 \geq 2 mg/mL (8.28 mM, 饱和度未知) 的澄清溶液。 以 1 mL 工作液为例，取 100 μ L 20.0 mg/mL 的澄清 DMSO 储备液加到 900 μ L 20% 的 SBE- β -CD 生理盐水水溶液中，混合均匀。 3.请依序添加每种溶剂： 10% DMSO →90% corn oil Solubility: \geq 2 mg/mL (8.28 mM); Clear solution																											

	<p>此方案可获得 ≥ 2 mg/mL (8.28 mM, 饱和度未知) 的澄清溶液, 此方案不适用于实验周期在半个月以上的实验。</p> <p>以 1 mL 工作液为例, 取 100 μL 20.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 玉米油中, 混合均匀。</p>
References	<p>[1]. Schafer, U., et al., <u>Presynaptic effects of moxonidine in isolated buffer perfused rat hearts: role of imidazoline-1 receptors and alpha2-adrenoceptors</u>. J Pharmacol Exp Ther, 2002. 303(3): p. 1163-70.</p> <p>[2]. Chan, C.K., et al., <u>Imidazoline receptors associated with noradrenergic terminals in the rostral ventrolateral medulla mediate the hypotensive responses of moxonidine but not clonidine</u>. Neuroscience, 2005. 132(4): p. 991-1007.</p>



源叶生物